MDGL rose 10.9% as a new U.S. patent is set to protect Rezdiffra's FDA-approved dosing regimen. The patent, valid through 2044, will be listed in the FDA's Orange Book, blocking generic competition.
Rezdiffra (resmetirom) is a prescription drug used to treat certain types of nonalcoholic steatohepatitis (NASH). Rezdiffra can cause side effects that range from mild to serious, such as diarrhea and ...
Rezdiffra (resmetirom) is a brand-name drug prescribed for a type of liver disease called metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH) ...
Rezdiffra (resmetirom) has potential interactions with other medications. These interactions could affect how well the drug works or cause harmful effects. Rezdiffra is used in adults to treat ...
In the pivotal Phase 3 MAESTRO-NASH biopsy trial, Rezdiffra achieved both fibrosis improvement and MASH resolution primary endpoints. Rezdiffra also reduced liver stiffness, liver fat, liver enzymes ...
Credit: Madrigal Pharmaceuticals. Rezdiffra is supplied in 60mg-, 80mg-, and 100mg-strength tablets and is distributed through a limited specialty pharmacy network. Rezdiffra should be avoided in ...
In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Rezdiffra has interactions with certain drugs, such as clopidogrel, atorvastatin, and gemfibrozil. Talk with your doctor to avoid potentially harmful effects from Rezdiffra interactions. Rezdiffra is ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Madrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark Office issued a Notice of Allowance for a new U.S. patent related to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results